These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11202536)

  • 1. Regulation of the compounding of positron emission tomography drugs.
    Hung JC
    Am J Health Syst Pharm; 2001 Jan; 58(2):134-9. PubMed ID: 11202536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explanations and unresolved issues pertaining to the development of the Nuclear Pharmacy Compounding Guidelines.
    Hung JC; Augustine SC; Cheng KT; Green RL; Hopkins WM; Laven DL; Nelson BR; Petry NA; Ponto JA; Quinton TM; Swanson DP
    J Am Pharm Assoc (Wash); 2002; 42(5):789-98. PubMed ID: 12269713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current good manufacturing practice for positron emission tomography drugs.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Dec; 74(236):65409-36. PubMed ID: 20169678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory Requirements for PET Drug Production.
    Schwarz SW; Dick D; VanBrocklin HF; Hoffman JM
    J Nucl Med; 2014 Jul; 55(7):1132-7. PubMed ID: 24914057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of various requirements of the quality assurance procedures for (18)F-FDG injection.
    Hung JC
    J Nucl Med; 2002 Nov; 43(11):1495-506. PubMed ID: 12411554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revocation of regulation on positron emission tomography drug products--FDA. Final rule; revocation.
    Fed Regist; 1997 Dec; 62(244):66522. PubMed ID: 10179303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compounding botanicals: a legal perspective.
    Valentino JG; Bormel FG
    J Am Pharm Assoc (Wash); 1999; 39(4):537-44. PubMed ID: 10467820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Food and Drug Administration requirements for testing and approval of new radiopharmaceuticals.
    Harapanhalli RS
    Semin Nucl Med; 2010 Sep; 40(5):364-84. PubMed ID: 20674596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential risks of pharmacy compounding.
    Gudeman J; Jozwiakowski M; Chollet J; Randell M
    Drugs R D; 2013 Mar; 13(1):1-8. PubMed ID: 23526368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current good manufacturing practices for PET drug products in the United States.
    Swanson D; Graham M; Heinonen TM; Libby P; Mills GQ
    J Nucl Med; 2009 Aug; 50(8):26N-8N. PubMed ID: 19652213
    [No Abstract]   [Full Text] [Related]  

  • 12. Applying Quality by Design Concepts to Pharmacy Compounding.
    Timko RJ
    Int J Pharm Compd; 2015; 19(6):453-63. PubMed ID: 26891559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compounding for animal patients: contemporary issues.
    Lust E
    J Am Pharm Assoc (2003); 2004; 44(3):375-84; quiz 384-6. PubMed ID: 15191248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulations for in vivo radiopharmaceuticals used for diagnosis and monitoring--FDA. Proposed rule.
    Fed Regist; 1998 May; 63(99):28301-9. PubMed ID: 10179873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of positron emission tomography in clinical medicine and the impact of drug regulation.
    Coleman RE; Robbins MS; Siegel BA
    Semin Nucl Med; 1992 Jul; 22(3):193-201. PubMed ID: 1523417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compounding pharmacy conundrum: "we cannot live without them but we cannot live with them" according to the present paradigm.
    Guharoy R; Noviasky J; Haydar Z; Fakih MG; Hartman C
    Chest; 2013 Apr; 143(4):896-900. PubMed ID: 23412546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA cGMP requirements for PET drugs.
    Norenberg JP; Schwarz S; VanBrocklin H
    J Nucl Med; 2011 May; 52(5):16N. PubMed ID: 21536923
    [No Abstract]   [Full Text] [Related]  

  • 18. The future of USP monographs for PET drugs.
    Schwarz S; Norenberg J; Berridge M; Dragotakes S; Hung J; Link J; Mason NS; Mattmuller S; Nickel RA; Packard A; Paolino J; Petry N; Ponto J; Quinton TM; Seifert KL; Swanson D; Weiner RE; Zigler S
    J Nucl Med; 2013 Mar; 54(3):472-5. PubMed ID: 23264689
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy.
    Pinkerton JV; Pickar JH
    Menopause; 2016 Feb; 23(2):215-23. PubMed ID: 26418479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. USP and PET radiopharmaceuticals: 1997 FDAMA puts standard-setting body at center of regulatory process.
    Hung JC; Callahan RJ
    J Nucl Med; 2004 Jan; 45(1):13N-14N, 16N. PubMed ID: 14734661
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.